Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous serum eye drops (ASEDs) are a blood-derived therapeutic used for the treatment of severe ocular surface diseases, such as persistent corneal epithelial defects (PEDs). The product is prepared by centrifuging a patient's own peripheral blood to separate the serum, which is then typically diluted to a 20% concentration with sterile saline. This serum contains a complex mixture of growth factors (including epidermal growth factor and transforming growth factor-beta), vitamins, fibronectin, and anti-inflammatory cytokines that mimic the biochemical properties of natural tears. These components promote corneal epithelial cell proliferation, migration, and adhesion, facilitating the healing of recalcitrant defects. E-DA Hospital has specifically evaluated the efficacy of 20% autologous serum eye drops when used in combination with silicone-hydrogel contact lenses to treat persistent epithelial defects and reduce recurrence rates.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous serum eye drops.